



**Grŵp Strategaeth Meddyginiaethau Cymru Gyfan  
All Wales Medicines Strategy Group**

**Meeting to commence at 09:30am on Tuesday, 2<sup>nd</sup> December 2025 at  
the  
All Nations Centre, Sachville Avenue, Cardiff, CF14 3NY**

**AGENDA**

**Enclosure**

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Approval of the minutes of the previous meeting** **1/AWMSG/1225**
5. **Chairman's report**
6. **AWTTC Programme Director's report**
7. **Venetoclax (Venclyxto®) with azacitidine** for the off-label treatment of relapsed/refractory acute myeloid leukaemia in adults following at least one line of intensive chemotherapy before or following allogenic haematopoietic stem cell transplant (HSCT) where it is not appropriate to offer intensive chemotherapy (OW32) – for endorsement **2/AWMSG/1225**
8. **All Wales Common Ailments Scheme formulary – Minor updates** -for information **3/AWMSG/1225**
9. **National Prescribing Indicators 2025–2026 Analysis of Prescribing Data to June** – for information **4/AWMSG/1225**
10. **NHS Wales inhaler carbon footprint report – August 2025** – for information **5/AWMSG/1225**
11. **Retirement of AWMSG endorsed medicines optimisation resources** - update for members - for information **6/AWMSG/1225**
12. **Any other business**
13. **Date of next meeting:  
Wednesday, 11<sup>th</sup> February 2025 at the All Nations Centre,  
Sachville Avenue, Cardiff, CF14 3NY**